Glycopyrronium Xiromed

Glycopyrronium Xiromed is a prescription inhalation medication containing the active ingredient glycopyrronium bromide. It is marketed in the European Union as an inhaled bronchodilator. As an anticholinergic (muscarinic antagonist), it selectively blocks muscarinic receptors in the airways, producing smooth‑muscle relaxation and improved airflow. It is prescribed to help manage breathlessness and reduced exercise tolerance in chronic obstructive pulmonary disease (COPD) for many patients through regular use.

Glycopyrronium Xiromed is indicated for the long‑term, once‑daily maintenance treatment of airflow limitation in patients with chronic obstructive pulmonary disease (COPD).

- Daily maintenance therapy to reduce breathlessness, wheeze, and cough associated with COPD. - Improves lung function measurements such as forced expiratory volume in one second (FEV1). - Helps lower the risk of moderate or severe COPD exacerbations requiring medical intervention. - Can be prescribed as monotherapy or combined with a long‑acting β2‑agonist for enhanced bronchodilation. - Appropriate for patients with moderate to severe airflow obstruction who require a long‑acting anticholinergic agent.

The safety profile of Glycopyrronium Xiromed includes both common and less frequent serious adverse events observed in clinical use, most of which are mild and reversible.

Common: - Dry mouth – reduced saliva, usually mild. - Cough – brief coughing after inhalation. - Throat irritation – mild discomfort in throat. - Upper respiratory tract infection – nasal congestion or sore throat. - Headache – mild to moderate head pain.

Serious: - Acute narrow‑angle glaucoma – sudden eye pain and visual changes. - Urinary retention – difficulty starting or maintaining urine flow. - Severe allergic reactions – rash, swelling, or anaphylaxis.

Before prescribing Glycopyrronium Xiromed, clinicians should consider several precautionary measures to ensure safe use in patients with COPD.

- Assess for a history of narrow‑angle glaucoma before initiating therapy. - Use caution in patients with urinary retention or prostate enlargement. - Monitor renal function, as the drug is primarily excreted unchanged by the kidneys. - Evaluate cardiovascular status, especially in patients with arrhythmias or recent myocardial infarction. - Advise patients to report persistent dry mouth or difficulty swallowing. - Educate patients on proper inhaler technique to minimize local irritation.

Glycopyrronium Xiromed may interact with other medications; awareness of potential interactions helps avoid reduced efficacy or increased adverse effects.

Avoid: - Other anticholinergic inhalers (e.g., tiotropium) due to additive anticholinergic effects. - Strong systemic anticholinergics (e.g., atropine) that may exacerbate dry mouth and urinary retention.

Use with caution: - Long‑acting β2‑agonists (LABA) when combined, monitor for bronchospasm. - Cholinesterase inhibitors used in Alzheimer’s disease (e.g., donepezil) as they may counteract bronchodilation. - Medications that affect renal excretion (e.g., NSAIDs) may alter drug clearance. - Diuretics that may cause electrolyte imbalance, potentially increasing risk of cardiac arrhythmias.